How GK-1 Peptide Affects Dendritic Cells in Cancer Treatment
Author Information
Author(s): Cervantes-Torres Jacquelynne, Hernández-Aceves Juan A., Gajón Martínez Julián A., Moctezuma-Rocha Diego, Vázquez Ramírez Ricardo, Sifontes-Rodríguez Sergio, Ramírez-Salinas Gemma L., Mendoza Sierra Luis, Alfonzo Laura Bonifaz, Sciutto Edda, Fragoso Gladis
Primary Institution: Universidad Nacional Autónoma de México
Hypothesis
GK-1 peptide activates dendritic cells through TLR4, enhancing their immune response against tumors.
Conclusion
GK-1 enters dendritic cells and activates them via TLR4, which may help in cancer treatment.
Supporting Evidence
- GK-1 was shown to delay tumor growth in mouse models.
- Bone marrow-derived dendritic cells were activated by GK-1 through TLR4.
- GK-1 uptake was more efficient at physiological temperature compared to lower temperatures.
- Significant differences in GK-1 uptake were observed at varying concentrations.
- GK-1 did not exhibit cytotoxic effects on dendritic cells at tested concentrations.
- Activation of dendritic cells by GK-1 was confirmed through increased cytokine production.
- Clathrin-mediated endocytosis was identified as a mechanism for GK-1 uptake.
- Comparative studies indicated that GK-1 has a lower affinity for TLR4 than LPS.
Takeaway
The GK-1 peptide helps immune cells called dendritic cells to fight cancer better by getting inside them and turning them on.
Methodology
The study involved in vitro and in vivo experiments to assess the uptake of GK-1 by dendritic cells and its effects on their activation.
Limitations
The study primarily used mouse models, which may not fully represent human responses.
Participant Demographics
The study used C57BL/6J and C3H/HeJ mice for experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website